Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.

  • Saeid Abediankenari Department of Immunology, Immonogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Ghasem Janbabaei Mollae Department of Hematology and Oncology, Mazandaran University of Medical Sciences, Sari, Iran.
  • Maryam Ghasemi Department of Pathology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Yousef Yousefzadeh Department of Immunology, Immonogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Masoud Bahrami Department of Orthopedic, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
  • Kamran Alimoghaddam Department of Hematology and Oncology, Transplantation Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Keywords: Dendritic cell, Lymphoma, Vaccine

Abstract

Dendritic cells (DCs) are professional antigen presenting cells that have a potential role in the initiating of immune responses. The cell vaccination is a new strategy in treatment of infectious diseases and cancers. In this study, we have generated monocyte-derived dendritic cells of lymphoma patient's peripheral blood mononuclear cells then; these cells were used as vaccine in lymphoma patients. We generated dendritic cell vaccine from lymphoma patient's blood monocytes with human interleukin-4, granulocyte monocyte colony stimulating factor and then, antigen-primed Dcs were administrated subcutaneously close to the inguinal lymph nodes after maturation of dendritic cells. After 7 days, we analyzed immune response in lymphoma patients with determining of LDH, Beta 2 Microglobulin, CD4+T cell percent, CD8+ Tcell percent and Tumor size before and after vaccination. Furthermore, phenotypic and functional analysis of dendritic cells was performed using anti CD83-FITC monoclonal antibodies. Before vaccination, the mean ± SD of LDH was 530.62±140.65 but after vaccination it was 459±109.45 that significantly different between experimental groups (P=0.002). In addition, the CD8+ T cells percentage significantly different between two groups (P=0.002). We concluded that the use of dendritic cell probably is one of the suitable noninvasive treatments for lymphoma patients that they have not response to chemical drugs.

References

Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010; 2(6):847-62.

Tawab A, Fan Y, Read EJ, Kurlander RJ. Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. Transfusion 2009;49(3):536-47

Hussin HN, Zulkifli FN, Phang KS, Cheong SK. Dendritic cell distribution in lymphomas. Malays J Pathol 2009;31(2):105-12

Sriram MI, Kanth SB, Kalishwaralal K, Gurunathan S. Antitumor activity of silver nanoparticles in Dalton,s lymphoma ascites tumor model. Int J Nanomedicine 2010;5:753-62

Saeid Abediankenari, Yousef Yousefzadeh, Hossein Azadeh, Mohammad Vahedi. Comparison of several maturation inducing factors in dendritic cell differentiation. Iran J Immuno 2010;l 7(2): 83-8

Mlief CJ. Cancer Immunotherapy by dendritic cells. Immunity 2008;29(3):372-83

Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58(4):732-6

Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma.CA Cancer J Clin 2010; 60(6):393-408.

Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development.J.Clin. Invest 2007; 117(5):1155-66.

Kim HS, Choo YS, Koo T Bang S, Oh TY, Wen J, et al. Enhancement antitumor in immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.Immunol Lett 2006;103(2):142-8.

Timmerman J.M, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50:507-29.

Nabavi H, Jasanbi B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M. A clinical gradepolyI:C-analogue( Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009; 27(1):107-15.

Schnurr M, Galambos P, Scholz C, Then F, Dauer M,Endres S, et al. Tumor cell lysate-pulsed human dendritic cells induce a Tcell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccine. Cancer Res 2001;61(17):6445-50

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65(1-2): 55-63

Finn OJ. Cancer immunology. N Engl J Med 2008:358(25);2704-15

Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunology 2003:21;685-711.

Steinman RM, Bancheau J. Taking dendritic cells into medicine. Nature 2007:449(7161);419-26.

Brossart P, Wirths S, Stuhler G, Reichardt V.L, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood 2000;96(9): 3102-8.

How to Cite
1.
Abediankenari S, Janbabaei Mollae G, Ghasemi M, Yousefzadeh Y, Bahrami M, Alimoghaddam K. Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells. Acta Med Iran. 51(5):284-288.
Section
Articles